After accounting for potential confounding by TP53 biallelic status, ovarian, colorectal, and endometrial cancers in the TP53 wild-type group showed significantly higher HRD scores in TMB-low samples (P<0.001, P<0.001, and P=0.001, respectively) (Supplementary figure 2K). Here, TP53 is linked to endometrial cancer.